Profound Medical (PROF) Liabilities and Shareholders Equity (2018 - 2026)

Profound Medical's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $73.5 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 20.69% year-over-year to $73.5 million in Q1 2026; TTM through Mar 2026 was $242.9 million, a 85.28% increase from a year earlier, with the FY2025 full-year figure at $77.5 million, up 10.31% from the prior year.
• Liabilities and Shareholders Equity fell to $73.5 million in Q1 2026 per PROF's latest filing, from $77.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $77.5 million in Q4 2025 and bottomed at $42.3 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $62.6 million (2022), against an average of $60.3 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 31.77% in 2023 and surged 59.78% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $64.4 million in 2022, then plunged by 31.77% to $44.0 million in 2023, then jumped by 59.78% to $70.2 million in 2024, then climbed by 10.31% to $77.5 million in 2025, then fell by 5.19% to $73.5 million in 2026.
• Per Business Quant, the three latest PROF Liabilities and Shareholders Equity figures stand at $73.5 million (Q1 2026), $77.5 million (Q4 2025), and $42.3 million (Q3 2025).